COLUMBIA, Md., Oct. 19 /PRNewswire-FirstCall/ — Celsion
Corporation (Nasdaq:
CLSN) announced today that two abstracts on the ThermoDox®
High Intensity Focused Ultrasound (HIFU) development program have
been delivered via oral presentation at the MR-guided Focused
Ultrasound 2010 2nd International Symposium. The abstracts
provide strong proof of concept, as well as the rationale and
support for future clinical studies, which will combine ThermoDox
with MR-guided HIFU for cancer indications. The symposium is
being held October 17-20, 2010 at the Westfields Marriott in
Dulles, VA .
The first abstract, titled “MR-guided High Intensity Focused
Ultrasound Enhances Targeted Drug Delivery of Low Temperature
Sensitive Liposomes in a Rabbit Vx2 Tumor Model,” is authored by
Ashish Ranjan from the National Institutes of Health, Bethesda, MD,
USA. The second abstract, titled “Thermally-mediated
Localized Drug Release Using MRI-Controlled Focused Ultrasound
Hyperthermia,” is authored by Robert Staruch from Sunnybrook Health
Sciences Centre and University of Toronto, Canada. Additional
co-authors from the two studies are from Duke University,
University of Helsinki, Finland, and Philips Healthcare. The
abstracts are available on the company’s website site at www.celsion.com.
“We are delighted to expand our HIFU program to leading oncology
research centers in the US, Canada and Europe,” said Michael H.
Tardugno, Celsion’s President and Chief Executive Officer. “We hope
to make a seamless transition to clinical studies in these and
additional countries based on the preclinical data that has been
developed through our joint research agreement with Philips
Healthcare. Celsion and Philips are now well positioned to
submit our clinical program for FDA review. Assuming we have
agreement, we expect
‘/>”/>
SOURCE